Omada Health (NASDAQ:OMDA – Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08, FiscalAI reports. The business had revenue of $91.31 million during the quarter. Omada Health had a net margin of 1.39% and a return on equity of 2.60%.
Here are the key takeaways from Omada Health’s conference call:
- Positive Sentiment: Omada reported record Q3 revenue of $91 million, up 34% year over year, and adjusted EBITDA of $12 million. It raised 2026 guidance to $344–$346 million in revenue and $32–$34 million in adjusted EBITDA.
- Positive Sentiment: Total members reached 1.134 million, up 36% year over year, while average program tenure rose to about two years and four months. Management said the stronger mix of diabetes and hypertension programs and lower cost to serve helped drive gross margin expansion and profitability.
- Positive Sentiment: Omada cited broader distribution through its PBM relationships and an HCSC agreement that could add an estimated 1.5 million covered lives across three states in 2027. The company said the fully insured benefit arrangement enables eligible members to enroll directly when it launches.
- Negative Sentiment: Management expects Q4 revenue below Q3 levels and a slight sequential decline in total members, reflecting typical seasonality and fewer new enrollments. The selling season has also extended into Q4 as employers take longer to weigh GLP-1 coverage and rising healthcare costs, leaving 2027 enrollment visibility unsettled.
Omada Health Stock Performance
Shares of Omada Health stock traded down $3.86 during trading hours on Friday, reaching $15.09. 4,709,304 shares of the company were exchanged, compared to its average volume of 1,032,454. Omada Health has a 1 year low of $10.28 and a 1 year high of $25.45. The stock’s fifty day moving average is $20.14 and its 200 day moving average is $17.74. The firm has a market cap of $923.81 million, a PE ratio of 71.86 and a beta of 2.13.
Key Omada Health News
Here are the key news stories impacting Omada Health this week:
- Positive Sentiment: Omada reported Q3 revenue of $91 million, up 34% year over year, and total members grew 36% to a record 1.1 million. Net income was $7 million versus a year-ago loss, while adjusted EBITDA increased to $12 million. The company also raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
- Positive Sentiment: Quarterly revenue exceeded FactSet’s estimate, and reported earnings also topped consensus estimates, providing evidence of stronger-than-expected operating performance. Earnings Flash: Q3 Revenue
- Neutral Sentiment: Unusual options activity was reported after Omada’s earnings, signaling heightened trading interest but not indicating a clear direction for the stock. Unusual Options Volume Report
- Negative Sentiment: Several analysts took a more cautious stance: Wells Fargo cut its price target to $19 and maintained an “equal weight” rating, while Zacks Research downgraded OMDA from “strong buy” to “hold.” Wells Fargo analyst actions Zacks Research analyst action
- Negative Sentiment: Barclays also lowered its target from $24 to $22, although it retained an “overweight” rating. Barclays analyst action
Wall Street Analyst Weigh In
OMDA has been the topic of several recent analyst reports. Weiss Ratings lowered shares of Omada Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, October 8th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a report on Friday, August 14th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Omada Health in a research report on Friday, September 11th. Barclays decreased their price target on Omada Health from $24.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Citizens Jmp raised their price target on Omada Health from $27.00 to $32.00 and gave the stock a “market outperform” rating in a research report on Friday, August 14th. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.33.
Check Out Our Latest Stock Report on OMDA
Insider Activity at Omada Health
In other Omada Health news, CEO Sean P. Duffy sold 21,572 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $23.62, for a total transaction of $509,530.64. Following the sale, the chief executive officer owned 411,861 shares in the company, valued at $9,728,156.82. This represents a 4.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Wei-Li Shao sold 8,866 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.02, for a total value of $221,827.32. Following the completion of the sale, the president directly owned 307,372 shares in the company, valued at $7,690,447.44. This represents a 2.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 119,014 shares of company stock worth $2,711,405. Company insiders own 6.38% of the company’s stock.
Hedge Funds Weigh In On Omada Health
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Omada Health during the second quarter worth approximately $48,775,000. Jefferies Financial Group Inc. purchased a new position in Omada Health in the second quarter worth approximately $15,016,000. Madryn Asset Management LP purchased a new position in Omada Health in the second quarter worth approximately $12,814,410. Walleye Capital LLC acquired a new position in Omada Health during the 2nd quarter worth approximately $11,648,000. Finally, Bank of America Corp DE acquired a new position in Omada Health during the 2nd quarter worth approximately $6,880,000.
About Omada Health
Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.
The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.
Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.
Read More
- Five stocks we like better than Omada Health
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
